Drug Database
HU

human albumin (Kedbumin)

✓ Approved

Kedrion · 细胞治疗 · 细胞治疗

什么是 human albumin?

human albumin 是一种细胞治疗,由Kedrion研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Kedbumin
公司Kedrion
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

human albumin 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAcute respiratory distress syndrome✓ Approved
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved
Injury, poisoning and procedural complicationsTraumatic shock✓ Approved
Injury, poisoning and procedural complicationsThermal burn✓ Approved

相关研究文献

PubMedBMC cancer2026-11-19

Treatment outcomes and immuno-nutritional biomarkers in patients with cervical esophageal squamous cell carcinoma treated with induction chemotherapy.

Ono Takeharu T, Nakata Yasunori Y, Chitose Shun-Ich SI, Sueyoshi Shintaro S et al.

Cervical esophageal squamous cell carcinoma arises below the upper esophageal sphincter, often causing dysphagia due to tumor progression. Therefore, some patients with cervical esophageal squamous cell carcinoma become malnourished. Due to its low incidence, limited information is available on prognostic immune-nutritional biomarkers. We retrospectively reviewed 47 patients with resectable cervical esophageal squamous cell carcinoma who underwent induction chemotherapy. Prognostic biomarkers were selected based on their 5-year area under the curve values. The association between the biomarkers and disease-free survival or overall survival was evaluated in univariable and multivariable analyses. The C-reactive protein-albumin-lymphocyte index and high-sensitivity modified Glasgow prognostic score were significantly associated with the induction chemotherapy response. Both the C-reactive protein-albumin-lymphocyte index and the high-sensitivity modified Glasgow prognostic score were significantly associated with disease-free survival and overall survival in univariable analysis. C-reactive protein-albumin-lymphocyte indices were significantly associated with disease-free survival and overall survival in multivariable analysis. The C-reactive protein-albumin-lymphocyte index is a useful prognostic treatment outcome biomarker in patients with cervical esophageal squamous cell carcinoma undergoing induction chemotherapy.

PMID 43052838
阅读全文 →
PubMedBMC cancer2026-11-19

Pulmonary embolism in lung cancer: a retrospective exploratory study.

Shang Junyi J, Wu Zhuhua Z, Jiang Miao M, Yuan Lin L et al.

Lung cancer is associated with a high risk of venous thromboembolism, and pulmonary embolism (PE) is a critical complication. The synchronous diagnosis of PE at the initial presentation of lung cancer presents diagnostic challenges and affects management. The predictive factors for this dual diagnosis remain poorly defined. A retrospective comparative study was conducted on 251 newly diagnosed lung cancer patients, including 79 with concurrent PE (observation group) and 172 without PE (control group). Demographic, clinical, laboratory, and tumor - related data were collected. Statistical analysis included univariate and multivariate logistic regression to seek independent risk factors and ROC curve analysis to evaluate their potential predictive performance. Univariate analysis revealed significant differences in multiple variables, including pericardial/pleural effusion, smoking index, hematologic parameters, coagulation markers, D - dimer, liver enzymes, albumin, and tumor markers (CEA, CA125, CA199) (P < 0.05). Multivariate logistic regression analysis indicated that smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent risk factors for synchronous pulmonary embolism in lung cancer patients. The combination of the six independent risk factors also demonstrated significant predictive potential (AUC = 0.857, sensitivity 79.1%, specificity 79.7%). Lung cancer patients presenting with synchronous PE exhibit a distinct clinical phenotype. The smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent predictive factors. D - dimer is a well diagnostic marker. These findings suggest a practical framework to help guide clinical suspicion and encourage targeted diagnostic evaluation for PE at the initial diagnosis of lung cancer, contributing to improved early intervention and patient outcomes.

PMID 43052863
阅读全文 →
PubMedNature biomedical engineering2026-11-19

Designer mucin-responsive nanomedicine for enhanced solid tumour penetration and therapy.

Yu Na N, Gong Ningqiang N, Liu Juan J, Zhong Haiping H et al.

While nanomedicines hold great promise for solid tumour therapy, their penetration and access to tumour cells is limited by large glycosylated proteins called mucins that are enriched in the tumour microenvironment. Here we show that mucins induce the disassembly of self-assembled mPEG-polyester micellar nanoparticles into smaller unimers. Leveraging this finding, we designed a mucin-responsive, paclitaxel-conjugated nanomedicine (mrPNM) whose unimers are capable of escaping the mucin-binding barrier. Following intravenous injection, this designer mucin-responsive nanomedicine exhibited markedly deeper penetration than the mucin-nonresponsive nanomedicine and albumin, resulting in 3.9- and 1.5-fold increases in tumour cell delivery, respectively, in a pancreatic mouse tumour model. The mrPNMs also achieved superior tumour growth inhibition compared to both the mucin-nonresponsive nanomedicine and Abraxane, the FDA-approved nanoparticle albumin-bound paclitaxel, in three solid tumour models. The mucin-responsive nanomedicine platform could provide a general strategy for improving the treatment of solid tumours.

PMID 43052497
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Ultrastretchable, Tissue-Matched Piezoelectric Gel with Preferentially Oriented Molecular Ferroelectric Crystallization.

Chen Hao-Ran HR, Zhang Yu-Hao YH, Ding Lei L, Li Jun-Yi JY et al.

Molecular ferroelectrics hold great potential for bioelectronics because of their excellent piezoelectric responses and biocompatibility. However, conventional integration into gel matrices suffers from two major drawbacks: solvent evaporation methods often yield brittle films with poor modulus matching with soft tissues, whereas physical blending typically leads to filler agglomeration and random crystal dispersion, making it difficult to achieve preferential crystal orientation and thereby limiting the piezoelectric performance. Here, we report an in situ crystallization strategy assisted by solvent exchange. This approach enables preferentially oriented triglycine sulfate (TGS) crystals to form within a polyacrylamide (PAM) network reinforced by glycidyl methacrylate-grafted bovine serum albumin (B-G). The B-G macromer strengthens the network through covalent integration and reversible hydrogen-bonding interactions. Subsequent treatment with a choline chloride/sorbitol deep eutectic solvent (DES) induced the preferential orientation of TGS within the gel matrix. The resulting gel achieved a fracture strain exceeding 2800%, maintained mechanical integrity over 10000 loading-unloading cycles, and exhibited mechanical compliance within the range of human soft tissues (10-5-10-4 Pa-1). In vitro and in vivo evaluations further demonstrated favorable biocompatibility and its potential for flexible piezoelectric sensing applications. This work provides molecular-level insight into the design of highly conformable piezoelectric gels containing preferentially oriented molecular ferroelectrics for tissue-matched biointerfaces.

PMID 43053447
阅读全文 →
PubMedAnalytical and bioanalytical chemistry2026-11-19

Immunoprecipitation based on freely diffusing biotinylated-Protein A and avidin: protein purification in the absence of a polymer resin substrate.

Razi Syeed Ghulam SG, Krichevsky Olga O, Wachtel Ellen E, Patchornik Guy G

This study presents an immunoprecipitation protocol that eliminates the standard polymer resin and, by so doing, greatly improves target yield, purity and efficiency. The goal is achieved via the use of three non-immobilized protein components: (i) a specific IgG antibody; (ii) a synthesized, biotinylated Protein A (B-ProA); and (iii) unconjugated native avidin. The three proteins are added sequentially, without intervening incubation time, to an aqueous medium containing the target molecule. With bovine serum albumin (BSA) as the model target protein, along with polyclonal anti-BSA IgG, quantitative precipitation of BSA was achieved in the presence of an E. coli lysate protein background. BSA was extracted from the pellet containing [B-ProA:Avidin:Anti-BSA IgG] in NaCitrate buffer, pH 3, with >95% yield (by densitometry) and >96% purity (by SDS-PAGE). We found that these optimal results could be obtained when approx. 75% of the lysine amino acids of Protein A had been biotinylated, as determined by the ninhydrin test. High-resolution scanning transmission electron microscopy (HR-STEM) imaging of the [B-ProA:Avidin] complex revealed the formation of macro-assemblies with a variety of architectures. Even when comparison was made with commercial agarose-Protein A beads in the presence of E. coli lysate as background, or in the presence of human plasma, with or without IgG antibodies as background, the relative superiority of the [B-ProA:Avidin] matrix was apparent.

PMID 43052481
阅读全文 →
PubMedHandbook of experimental pharmacology2026-11-19

Boron Clusters in Oral Cancer Therapy: Advances and Prospects.

Monti Hughes Andrea A

Head and neck cancer is a challenging and complex disease, with oral squamous cell carcinoma being one of the most frequent tumors. Conventional therapies are often limited by toxicity to critical surrounding structures and organs. Boron neutron capture therapy (BNCT) is a selective particle radiotherapy therapeutically useful for the treatment of head and neck tumors. New boron compounds are currently under development, with boron clusters emerging as ideal BNCT carriers due to their unique chemical properties and capacity to be functionally modified. Animal models that closely recapitulate human oral carcinogenesis and therapeutic response-i.e., simultaneous evaluation of tumor control and toxicity-are highly valuable. The hamster cheek pouch oral cancer model is one of the most widely used for studying oral tumors and BNCT. In this chapter, advances in the development of boron clusters and their use in the hamster cheek pouch oral cancer model are described, highlighting the advantages of this animal model for assessing systemic toxicity, boron biodistribution and microdistribution in the tumor, therapeutic effect and mucositis, a common BNCT-induced adverse effect. A comparative analysis, in this animal model, between BPA/BNCT and BNCT mediated by the boron clusters GB-10, Na[o-COSAN], MAC-TAC liposomes and closo-dodecaborate-conjugated albumin showed that they were capable of reducing moderate/severe mucositis associated with tumor control. The chapter concludes with perspectives on strategies to optimize BNCT mediated by these boron clusters and on how to accelerate their translation into clinical practice.

PMID 43052487
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多human albumin